In 2025, Bb Biotech completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Bb Biotech has also provided a category-level breakdown for 5 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 7a | 12a | 10a | |
Total Scope 2 | ||||
Unspecified Calculation Method | 7a | 10a | 23a | |
Total Scope 3 | 717a | 581a | 575a | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.009a | 0.0968a | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Bb Biotech amounted to 14 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Bb Biotech decreased by 36.36%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Bb Biotech were 7 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Bb Biotech's Scope 1 emissions have decreased by 78.13%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2024), Bb Biotech's Scope 1 emissions decreased by 41.67%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Bb Biotech reported Scope 2 greenhouse gas (GHG) emissions of 7 tCO₂e without specifying the calculation method.a
Since 2020, Bb Biotech's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 84.09%, reflecting a declining long-term trend in Scope 2 emissions over time.a
Compared to the previous year (2024), Bb Biotech's Scope 2 emissions (Unspecified Calculation Method) fell by 30% in 2025, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2025, Bb Biotech reported its Scope 2 emissions using an unspecified methodology.a
In 2025, Bb Biotech reported 717 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Bb Biotech includes a breakdown across 4 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Bb Biotech reported total Scope 3 emissions of 717 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2020, Bb Biotech's Scope 3 emissions have increased by 1,692.5%, reflecting a rising long-term trend in Scope 3 emissions over time.a
Compared to the previous year (2024), Bb Biotech's Scope 3 emissions increased by 23.41%, suggesting that the company faced challenges in reducing emissions across its value chain.a
In 2025, Bb Biotech reported emissions for 4 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
In 2025, the largest contributors to Bb Biotech's Scope 3 emissions were:a
In 2025, Bb Biotech reported Scope 1 greenhouse gas (GHG) emissions of 7 tCO₂e and total revenues of USD 778 millions. This translates into an emissions intensity of 0.01 tCO₂e per millions USD.a
In 2025, Bb Biotech reported a Scope 1 emissions intensity of 0.01 tCO₂e per millions USD. Compared to the peer group median of 2.27, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Bb Biotech ranked 2 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Bb Biotech among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Bb Biotech reported a total carbon footprint of 731 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 21.23% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Bb Biotech's total carbon footprint was Scope 3 emissions, accounting for 98.08% of the company's total carbon footprint, followed by Scope 1 emissions at 0.96%.a